According to S*BIO Pte Ltd officials, company will initiate Phase 2 clinical trial of SB939, its novel orally-active HDAC inhibitor, in patients with recurrent or metastatic prostate cancer (HRPC).
The study’s primary objective is to determine the compound’s efficacy, which will be measured by the prostate-specific antigen (PSA) responses and progression free survival, in HRPC patients who received up to one prior chemotherapy regimen.
Among secondary objectives company today announced the determination of objective response, the response duration in patients with measurable disease at baseline, and the tolerability and toxicity of SB939 in the study’s patient population as well as investigation of biomarkers in circulating tumour cells.
No User Responded In This Post
Before Leave Your Comments Here Click Below On Our Sponsors...